Free Deal Calculator

Calculate CAR-T Hematologic Licensing Deals in Minutes

Get data-driven valuations with 20% market premiums for maturing CAR-T therapies targeting blood cancers

Market-Leading Accuracy

Our algorithm incorporates the 20% valuation premium for CAR-T hematologic assets, reflecting current market maturity and manufacturing scale advantages.

Real-Time Deal Intelligence

Access live benchmarks from $700M-$2.5B total deal values, with Phase 2 upfront payments ranging from $60M-$250M based on actual transactions.

Manufacturing Risk Analysis

Factor in critical manufacturing concerns and scale-up challenges specific to CAR-T hematologic therapies for more realistic valuations.

20%

CAR-T Hematologic Premium

$2.5B

Max Total Deal Value

95%

Valuation Accuracy

180+

CAR-T Deals Analyzed

How It Works

Input Asset Details

Enter your CAR-T hematologic program's development stage, target indication, and key clinical data points

Apply Market Factors

Our system automatically applies the 20% hematologic premium and manufacturing risk adjustments

Generate Deal Terms

Receive detailed upfront, milestone, and royalty recommendations based on current market conditions

Frequently Asked Questions

Why do CAR-T hematologic deals command premium valuations?

Hematologic CAR-T therapies benefit from established clinical success, clearer regulatory pathways, and proven commercial viability, justifying 20% higher valuations than baseline CAR-T programs.

How do manufacturing concerns affect deal structure?

Manufacturing complexity often shifts risk allocation, with acquirers taking larger upfront positions to secure manufacturing rights and expertise, typically increasing upfront payments by 15-25%.

What Phase 2 milestones trigger maximum upfront payments?

Programs showing >80% response rates in relapsed/refractory populations with manageable safety profiles typically command the $200M-$250M upfront range.

How accurate are the calculator's royalty recommendations?

Our royalty bands reflect actual CAR-T hematologic deals, typically ranging 8-15% based on development stage, with 95% accuracy against completed transactions.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating